Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF) (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $19.7 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 1.77% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.0 million (up 73.47% YoY) and the FY2025 annual result came in at $83.7 million, up 129.36% from the prior year.
• Depreciation & Amortization (CF) climbed to $19.7 million in Q1 2026, from $19.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $23.8 million in Q2 2025 to a low of $2.8 million in Q1 2022.
• A 5-year average of $10.4 million and a median of $7.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) fell 5.01% — and 2025, when it jumped 192.35%.
• Tracing RXRX's Depreciation & Amortization (CF) over 5 years: stood at $3.2 million in 2022, then surged by 135.0% to $7.6 million in 2023, then surged by 71.47% to $13.0 million in 2024, then soared by 50.4% to $19.5 million in 2025, then rose by 1.0% to $19.7 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $19.7 million (Q1 2026), $19.5 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.